Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Pre-emptive Local Anesthesia and Emergence Behavior After Pediatric Dental General Anesthesia

NCT07604337 · tracked via the Priya Life Science Turkey tracker
Sponsor
seher orbay yasli
Phase
Not applicable
Started
2026-06
Last updated
2026-06-09

Condition(s) studied

Emergence DeliriumPediatric Dental General AnesthesiaPostoperative Recovery

Investigational drug(s) / intervention(s)

Pre-emptive Local AnesthesiaArticaine Hydrochloride With Epinephrine

Pre-emptive Local Anesthesia: Pre-emptive local anesthesia will be administered by the pediatric dentist before the dental procedure according to the planned treatment area. The local anesthetic agent, total volume, total dose, dose per kilogram, and injection sites will be recorded.

Articaine Hydrochloride With Epinephrine: Articaine hydrochloride with epinephrine will be administered as local anesthesia by the pediatric dentist before the dental procedure in participants randomized to the pre-emptive local anesthesia group. The total volume, total dose, dose per kilogram, and injection sites will be recorded.

Study summary

This study will evaluate whether pre-emptive local anesthesia improves early recovery after ambulatory pediatric dental general anesthesia. Children aged 7-12 years scheduled for dental treatment under general anesthesia will be randomly assigned to receive either pre-emptive local anesthesia or no local anesthesia. Emergence delirium, pain, sedation level, and recovery quality will be assessed during the early postoperative period. The primary outcome will be the longitudinal Pediatric Anesthesia Emergence Delirium Scale score during the first 30 minutes in the post-anesthesia care unit.

Eligibility

Sex
ALL
Min age
7 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: * Children aged 7 to 12 years * ASA physical status I or II * Scheduled for ambulatory dental treatment under general anesthesia * Ability to understand and respond to age-appropriate pain and recovery assessment tools * Written informed consent obtained from a parent or legal guardian * Child assent obtained when appropriate Exclusion Criteria: * Known allergy or contraindication to local anesthetic agents * Developmental delay or cognitive impairment preventing assessment * Autism spectrum disorder or severe behavioral disorder * Neurological disease affecting behavior or consciousness * Chronic analgesic or sedative medication use * Severe hepatic, renal, cardiac, or respiratory disease * Emergency dental procedure * Need for postoperative hospital admission * Inability to complete postoperative assessment tools

Primary outcome measure(s)

  • Pediatric Anesthesia Emergence Delirium Scale Score During Early Recovery — PACU minutes 0, 5, 10, 15, and 30
    Emergence delirium will be assessed using the Pediatric Anesthesia Emergence Delirium Scale. The scale includes five items: eye contact, purposeful actions, awareness of surroundings, restlessness, and consolability. Each item is scored from 0 to 4, with a total score ranging from 0 to 20. Higher scores indicate more severe emergence delirium symptoms. Assessments will be performed only when the Richmond Agitation-Sedation Scale score is ≥ -1.

Trial sites (1)

FacilityCityRegionStatus
Erciyes University Faculty of Dentistry Kayseri Kayseri
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07604337 on ClinicalTrials.gov ↗ ← All trials in Turkey